Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call
Taysha Gene Therapies (TSHA) reported Q2 2026 earnings, with a net loss of $46.6M, up from $26.9M in the prior year. R&D expenses rose to $38.6M, and cash reserves totaled $455.4M. The company completed dosing in REVEAL and ASPIRE trials for TSHA-102, a gene therapy for Rett syndrome, with 100% of Part A patients meeting responder status. Management expects regulatory discussions in H1 2027 and extended cash runway into H2 2028.
How this was made
The 30-second read
Why it matters
The call combines clinical execution milestones (dosing completion, responder rate), manufacturing readiness (PPQ campaign timing, Catalent expansion), and financing (follow-on proceeds) to shape the probability-weighted path to a BLA submission.
Market read
Traders can update expectations for the BLA timeline and near-term catalysts based on dosing completion, interim analysis framing, and cash runway extension.
What to watch
The article flags an SAE related to peripheral sensory neuropathy and notes EEG remains exploratory, which could temper enthusiasm despite strong functional endpoints.
Background
Taysha is advancing TSHA-102, an intrathecal AAV9 gene therapy for Rett syndrome, toward BLA-enabling activities and FDA discussions.
Ticker impact
Taysha reported completion of dosing in the REVEAL pivotal and ASPIRE trials for TSHA-102, with 100% responder status by 12 months in Part A.
Bullish bias with potential volatility into first-half 2027 FDA feedback and 6-month interim top-line readout.
The article discloses multiple new, decision-relevant datapoints: dosing completion, responder rate exceeding the 33% threshold, manufacturing PPQ completion expected in Q4 2026, and a $230M follow-on financing extending runway into H2 2028.
Market effects
Supports sentiment for gene therapy peers by reinforcing payer and manufacturing readiness narratives tied to BLA-enabling work.
Limited direct regional spillover; primarily US biotech/gene-therapy investor sentiment.
Rett syndrome market sizing and EU/UK target population framing may influence global rare-disease gene therapy expectations.
Counterpoint
Responder rate and functional gains may not fully translate into regulatory approval or durable benefit, and single-arm designs can face scrutiny.
Key entities
- companyTaysha Gene Therapies, Inc.
Subject of the earnings call, reporting Q2 2026 financials and TSHA-102 clinical and regulatory progress.
- productTSHA-102
Gene therapy candidate for Rett syndrome discussed across REVEAL and ASPIRE trials.
- partnerCatalent
Manufacturing partner expanded for commercial supply capacity and FDA-licensed facility work.
- regulatorFDA
Management expects feedback on the BLA pathway in the first half of 2027.
